Holen Sie sich die Stockscreener-App
13.35
3.25%
0.42
Handel nachbörslich:
13.30
-0.05
-0.37%
Schlusskurs vom Vortag:
$12.93
Offen:
$13
24-Stunden-Volumen:
916.06K
Relative Volume:
0.87
Marktkapitalisierung:
$1.12B
Einnahmen:
$31.37M
Nettoeinkommen (Verlust:
$-231.96M
KGV:
-4.2204
EPS:
-3.1632
Netto-Cashflow:
$-243.39M
1W Leistung:
+12.94%
1M Leistung:
-3.05%
6M Leistung:
-9.74%
1J Leistung:
+135.04%
1-Tages-Spanne:
$12.74
$13.35
1-Wochen-Bereich:
$11.91
$13.43
52-Wochen-Spanne:
$5.57
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
13.35 | 1.08B | 31.37M | -231.96M | -243.39M | -3.1632 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears - Yahoo Finance
EYPT: DURAVYU Phase III data expected in August, targeting six-month dosing and U.S. launch in 2025 - TradingView
(EYPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets - Yahoo Finance
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint lines up Goldman Sachs, Jefferies, Stifel fireside chats - Stock Titan
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Should I Buy EYPT (EyePoint Pharmaceuticals, Inc.) | AI Analysis, Technical & News Insights - Kavout
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - Quiver Quantitative
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - Yahoo Finance
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - Sahm
EyePoint’s DURAVYU Receives Third Consecutive Positive DSMC Review for Wet AMD - The Clinical Trial Vanguard
EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review - Moomoo
EyePoint (EYPT) Receives Positive Review for Duravyu Trials - GuruFocus
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review - AD HOC NEWS
EyePoint Announces Third Positive DSMC Review for DURAVYU Phase 3 Wet AMD Trials, Topline Data Expected Mid-2026 - Minichart
EyePoint's late-stage eye drug trials to continue after safety panel review - TradingView
EyePoint’s wet AMD trial continues after safety review By Investing.com - Investing.com Australia
Eyepoint announces third consecutive positive DSMC recommendation for phase 3 wet AMD trials for Duravyu(TM), building confidence ahead of mid-2026 topline data - marketscreener.com
EyePoint Advances DURAVYU Phase 3 Wet AMD Program - TipRanks
EyePoint’s wet AMD trial continues after safety review - Investing.com India
EyePoint receives third positive DSMC review; Phase 3 topline data on track for mid-2026 - TradingView
Third positive DSMC review backs EyePoint (EYPT) Phase 3 DURAVYU wet AMD trials - Stock Titan
Eyepoint Inc Announces Third Consecutive Positive Dsmc Recommendation for Phase 3 Wet Amd Trials for Duravyu - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
EyePoint: DURAVYU's Durability Could Drive Significant Upside (NASDAQ:EYPT) - Seeking Alpha
Adage Capital files amendment: 3,300,000 shares in EyePoint (EYPT) disclosed - Stock Titan
TradingKey - TradingKey
Liquidity Mapping Around (EYPT) Price Events - Stock Traders Daily
EyePoint Pharmaceuticals stock (US30233B1098): Trading at discount to fair value estimates - AD HOC NEWS
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Is It Too Late To Consider EyePoint (EYPT) After A 133% One-Year Surge? - simplywall.st
HC Wainwright Issues Pessimistic Forecast for EYPT Earnings - MarketBeat
Is EyePoint’s Revenue Slide and DURAVYU Cash Runway Altering The Investment Case For EyePoint (EYPT)? - simplywall.st
H.C. Wainwright Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
EyePoint, Inc. (EYPT) Stock Analysis: A Biotech Gem With 177% Potential Upside - DirectorsTalk Interviews
EyePoint Announces First Quarter 2026 Revenue Results - VisionMonday.com
EyePoint (EYPT) Reports Strong Q1 Revenue and Anticipates Key Tr - GuruFocus
RBC Capital Maintains EyePoint(EYPT.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
EYPT Maintains Rating by RBC Capital -- Price Target Lowered to $37 - GuruFocus
EyePoint 1Q Loss $84.8M >EYPT - Moomoo
[10-Q] EyePoint, Inc. Quarterly Earnings Report - Stock Titan
EyePoint (EYPT) Q1 2026 Earnings Transcript - AOL.com
MSN Money - MSN
Guggenheim reiterates Buy on EyePoint stock, cites trial progress By Investing.com - Investing.com India
RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating - marketscreener.com
A Quick Look at Today's Ratings for EyePoint(EYPT.US), With a Forecast Between $20 to $43 - Moomoo
EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Number of shareholders of EyePoint, Inc. – LSX:A2QJRU - TradingView
Finanzdaten der Eyepoint Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Eyepoint Inc-Aktie (EYPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Sale |
15.00 |
2,437 |
36,555 |
0 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):